The successful pricing of Contineum Therapeutics' IPO at $16 per share for 6,875,000 Class A common shares indicates a positive market reception and investor confidence in the company's potential. This event is likely to generate significant interest among investors, potentially leading to a short-term increase in the stock price as the market responds to the new availability of shares and the company's public market debut.